TANAKA Norina    Department   School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine    Position   Assistant Professor
Article types	Original article
Language	English
Peer review	Peer reviewed
Title	High PRAME expression is associated with poor survival and early disease progression in myelodysplastic syndromes with a low bone marrow blast percentage.
Journal	Formal name：Leukemia & lymphoma Abbreviation：Leuk Lymphoma ISSN code：10292403/10268022
Domestic / Foregin	Foregin
Volume, Issue, Page	62(10),pp.2448-2456
Author and coauthor	Shiseki Masayuki†*, Ishii Mayuko, Ohwashi Mari, Wang Yan-Hua, Tanaka Norina, Osanai Satoko, Yoshinaga Kentaro, Mori Naoki, Tanaka Junji
Publication date	2021/10
Summary	We investigated the clinical implications of preferentially expressed antigen in melanoma (PRAME) expression in bone marrow cells of 116 patients with myelodysplastic syndromes (MDS). Quantitative RT-PCR was carried out to examine the PRAME expression level. High PRAME expression was observed in MDS patients classified into higher revised International Prognostic Scoring System (IPSS-R) risk categories (Very high and High) with a high bone marrow blast percentage (5% or higher). Kaplan-Meier analysis demonstrated that high PRAME expression is significantly associated with a poorer overall survival (OS) in MDS patients with a low bone marrow blast percentage (less than 5%) (log-rank test p = .0014) and those classified into lower IPSS-R risk categories (Very Low, Low, and Intermediate) (log-rank test, p = .0035). In contrast, there was no significant association between PRAME expression and OS in MDS patients with a high bone marrow blast percentage or those classified into higher IPSS-R risk categories. In addition, high PRAME expression was associated with early disease progression in MDS patients with a low bone marrow blast percentage. This study suggested PRAME expression to be a prognostic factor in MDS.
DOI	10.1080/10428194.2021.1919659
PMID	34013846